Coronavirus Disease 2019 (COVID-19) Situation Report

Data as reported by national authorities by 24:00 local time 10 January 2021

Situation Report No. 211 - Kingdom of Bahrain

11th of January, 2021



	Gl	obal	Eastern Mediterranean Region		
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths	
Total	88,383,771	1,919,126	5,149,132	124,836	
New	790,456	12,454	25,132	350	

Kingdom of Bahrain

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests
Total	95,558	92,362	356	2,840	16	2,474,881
New	241	249	1	-	-	11,720

HIGHLIGHTS

- The mortality was a 74 year old Female Bahraini Citizens.
 Increasing number of dittens and residents continue to take COVID-19 vaccine in Bahrain; and Ministry of Health (MOH) revealed that total number of individual swacinated as of 10 January 2021 is 89,250.
 Ministry of Health revealed that 50% of existing COVID-19 cases in Bahrain are contracted through contacts with relatives during femily relatives. family gathe

family gatherings. • Ministry of Health urges compliance to all public health precautionary measures to curb COVID-19 infections. • National Medical Taskforce provided updated traveling procedures for arrivals into Bahrain via King Fahd Caucevay. • WHO: New research helps to increase understanding of the impact of COVID-19 organit women and their bables; see link below. • WHO: Theregonding to non-communicable diseases during and beyond the COVID-19 prandemic; see link below. • WHO: Temergency Global Supply Chain System(COVID-19) catalogue; see link below. • WHO: Temergency Global Supply Chain System(COVID-19) catalogue; see link below. • WHO: Temergency Global Supply Chain System(COVID-19) catalogue; see link below. • WHO: Stafe values framework for the allocation and prioritization of COVID-19 vaccination; see link below. • WHO: Stafe values framework for the allocation and prioritization of COVID-19 vaccination; see link below. • WHO: Stafe values framework for the allocation and prioritization of COVID-19 vaccination; see link below. • WHO: Stafe values framework for the allocation and prioritization of COVID-19 vaccination; see link below. • WHO: As COVID:19 spread accelerates ,IHR Emergency Committee urges focus on measures that work; see link below. • WHO: Chepting for aCOVID-19 vaccine; see link below. • WHO: Chepting Long Cancine; see link below.

WHO Living Guideline: The rapeutics and COVID-19; see link below.
 WHO: Interim guidance on Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19; see link below.
 WHO: Livinene to recommendations: COVID-19 mitigation in the aviation sector; see link below.
 WHO: Checklist to support schools re-opening and preparation for COVID-19 resurgences or similar public health crises; see link below.

below WH0: COVID-19 vaccine introduction and deployment costing tool; see link below. WH0: Energency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 place bo-controlled vaccine trials and trial unbinding; see link below. WH0: Considerations for implementing a risk-based approach to international travel in the context of COVID-19; see link below. WH0: COVIA Announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021; see link below.

see link below. • WHO: Rational use of personal protective equipment for coronavirus disease (COVID-19) and considerations during severe shortages;

see link below WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access; see link

WHO: Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health; see link below.
 WHO: Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing; see link


IMPORTANT LINKS

Daily COVID-19 updates on MoH website:	
https://www.moh.gov.bh/	
WHO's COVID-19 weekly situation reports:	
https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200817-weekly-epi-update 1.pdf?sfvrsn=b6d49a76 4	
WHO's COVID-19 Dashboard: https://covid19.who.int/	
WHO: New research helps to increase understanding of the impact of COVID19 for pregnant women and their babies:	
https://www.who.int/news-room/detail/01-09-2020-new-research-helps-to-increase-understanding-of-the-impact-of-covid-19-for-pregnant-women-and-their-babies	
WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic : https://bit.ly/25vds0r	
WHO :Emergency Global Supply Chain System(COVID-19) catalogue:	
https://www.who.int/publications/i/item/emergency-global-supply-chain-system-(covid-19)-catalogue	
•WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapidimmun oassays :bit.ly/2IfOjVF	
WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination :bit.ly/2J0wxWQ	
WHO: interim guidance Operational considerations for COVID19 surveillance using GISRS: https://bit.lv/34APN5G	
WHO: As COVID19 spread accelerates ,IHR Emergency Committee urges focus on measures that work : https://bit.ly/37ZI0I6	
WHO: Thepush for aCOVID-19 vaccine :https://bit.ly/3mS3hAa	
WHO-ICMRA joint statement on the need for improved global regulatory alignment on COVID-19 medicines and vaccines: bit.ly/3panKSM	
WHO Living Guideline: The rapeutics and COVID-19: https://www.who.int/publications/i/item/therapeutics-and-covid-19-living-guideline	
• WHO: Interim guidance on Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19: https://www.who.int/publications/i/item/WHO-2019	
nCoV-HCF assessment-Products-2020.1	
WHO: Evidence to recommendations: COVID-19 mitigation in the aviation sector:	
https://www.who.int/publications/i/item/evidence-to-recommendation-covid-19-mitigation-in-the-aviation-sector	
WHO: Checklist to support schools re-opening and preparation for COVID -19 resurgences or similar public health crises:	
https://www.who.int/publications/i/item/9789240017467	
COVID-19 vaccine introduction and deployment costing tool: https://www.who.int/publications/i/item/10665337553	
• WHO: Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 placebo-controlled vaccine trials and trial	e -
unblinding:	
https://www.who.int/publications/i/item/WHO-2019-nCoV-Policy_Brief-EUD_placebo-controlled_vaccine_trials-2020.1	
 WHO: Considerations for implementing a risk-based approach to international travel in the context of COVID-19: 	
https://www.who.int/publications/i/item/WHO-2019-nCoV-Risk-based-international-travel-2020.1	
WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19:	
https://www.who.int/publications/i/item/WHO-2019-nCoV-Risk-based_international_travel-Assessment_tool-2020.1	
WHO: COVAX Announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021:	7
https://www.who.int/news/item/18-12-2020-covax-announces-additional-deals-to-access-promising-covid-19-vaccine-candidates-plans-global-rollout-starting-q1-2021	
 WHO: Rational use of personal protective equipment for coronavirus disease (COVID-19) and considerations during severe shortages: 	
https://www.who.int/publications/i/item/rational-use-of-personal-protective-equipment-for-coronavirus-disease-(covid-19)-and-considerations-during-severe-shortages	6
 WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access: 	0
https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access	
WHO: Genomic sequencing of SARS -CoV-2: a guide to implementation for maximum impact on public health:	5
https://www.who.int/publications/i/item/9789240018440	5
 WHO: Interim recommendations for use of the Pfizer –BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing: 	
https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-BNT162b2-2021.1	4
	4
	_
IMPORTANT CONTACTS	з
	3

• The National Focal Person is Dr. Najat Mohamed Abulfateh, email: NAli5@health.gov.bh

• International Health Regulations focal person is Dr. Kubra Salman,

email: knasser@health.gov.bh



Total Number of Cases



Number of New Deaths

